Details of Disease

General Information of Disease (ID: DISDJJ4U)

• Disease Name: Merkel cell carcinoma
• Synonyms: Merkel cell carcinoma; trabecular carcinoma; trabecular adenocarcinoma (morphologic abnormality); trabecular adenocarcinoma; trabecula adenocarcinoma
• Disease Class: 2C34: Neuroendocrine carcinoma
• Definition: A malignant epithelial neoplasm characterized by the presence of a trabecular glandular architectural pattern.
• Disease Hierarchy:
  DIS3IHTY: Adenocarcinoma
  DISDJJ4U: Merkel cell carcinoma
• ICD Code:
  ICD-11: ICD-11: 2C34
  ICD-10: ICD-10: C44
• Disease Identifiers:
  MONDO ID: MONDO_0002822
  UMLS CUI: C0302182
  MedGen ID: 86214
  SNOMED CT ID: 29792007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Avelumab	DMSZLJR	Approved	Monoclonal antibody	[1]
Bavencio	DMU9C8F	Approved	Monoclonal antibody	[2]
Retifanlimab	DMRKTCP	Approved	Antibody	[3]
HBI-8000	DMDWYUN	Registered	Small molecular drug	[4]

This Disease is Treated as An Indication in 18 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AMD-070	DMVOY6B	Phase 3	Small molecular drug	[4]
INCB24360	DMIJGT9	Phase 3	Small molecular drug	[4]
Seviprotimut-L	DMQW6B6	Phase 3	NA	[5]
OT-101	DMCTRLN	Phase 2/3	Antisense oligonucleotide	[6]
AMG 232	DM65PTO	Phase 2	NA	[7]
GRN-1201	DMXOYIH	Phase 2	NA	[8]
GSK3377794	DMQ4RWW	Phase 2	NA	[4]
HaNK	DMV05CY	Phase 2	Cell therapy	[9]
Interleukin-12 gene therapy	DMPO5IC	Phase 2	NA	[10]
MORAb-004	DMGK1JE	Phase 2	NA	[6]
NANT merkel cell cancer vaccine	DMMZIVV	Phase 2	NA	[6]
Ontuxizumab	DM0FJIE	Phase 2	Antibody	[8]
Telomelysin	DMNNDMA	Phase 2	NA	[8]
IMCnyeso	DMWVI0O	Phase 1/2	NA	[6]
MAGE-A10 TCR	DM6H3YS	Phase 1/2	NA	[6]
Ifx-Hu2.0	DM637SC	Phase 1	Vaccine	[11]
MCC1 TCR	DM6008I	Phase 1	TCR-T cell therapy	[12]
TTI-621	DMDNPAV	Phase 1	Recombinant protein	[6]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] ClinicalTrials.gov (NCT03599713) A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201). U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT03787602) This Study Evaluates KRT-232, a Novel Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients With (p53WT) Merkel Cell Carcinoma Who Have Failed Anti-PD-1/ PD-L1 Immunotherapy. U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] ClinicalTrials.gov (NCT03853317) QUILT-3.063: A Phase 2 Study of Combination Therapy With an IL-15 Superagonist (N-803), Off-the-shelf CD16-targeted Natural Killer Cells (haNK), and Avelumab Without Cytotoxic Chemotherapy in Subjects With Merkel Cell Carcinoma (MCC) That Has Progressed on or After Treatment With a Checkpoint Inhibitor. U.S.National Institutes of Health.
• [10] Clinical pipeline report, company report or official report of OncoSec Medical.
• [11] ClinicalTrials.gov (NCT04160065) Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC. U.S. National Institutes of Health.
• [12] Clinical pipeline report, company report or official report of bluebird bio.